Kathryn E Stephenson

List of Publications by Year in Descending Order

41 papers	2,692 citations	22 h-index	41 g-index
41 ext. papers	3,741 ext. citations	20.2 avg, IF	5.25 L-index

#	Paper	IF	Citations
41	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.. *Npj Vaccines*, **2022**, 7, 2	9.5	0
40	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective.. *Open Forum Infectious Diseases*, **2022**, 9, ofac124	1	3
39	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. *Nature Medicine*, **2021**, 27, 1718-1724	50.5	5
38	Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. *Clinical Infectious Diseases*, **2021**, 73, e3996-e4004	11.6	43
37	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1535-1544	27.4	139
36	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. *Annals of Internal Medicine*, **2021**, 174, 585-594	8	14
35	Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. *New England Journal of Medicine*, **2021**, 384, 1824-1835	59.2	575
34	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. *Nature*, **2021**, 596, 268-272	50.4	122
33	Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19 **2021**,		10
32	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. *New England Journal of Medicine*, **2021**, 385, 951-953	59.2	77
31	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. *Lancet Infectious Diseases, The*, **2020**, 20, 1061-1070	25.5	15
30	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). *Lancet HIV,the*, **2020**, 7, e410-e421	7.8	11
29	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. *Annual Review of Immunology*, **2020**, 38, 673-703	34.7	40
28	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. *Nature Medicine*, **2020**, 26, 228-235	50.5	30
27	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. *Cell*, **2020**, 183, 1354-1366.e13	66.2	108
26	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. *Cell Reports*, **2020**, 33, 108502	10.6	10
25	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. *Lancet HIV,the*, **2019**, 6, e259-e268	7.8	87

24	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. *Cell Host and Microbe*, **2019**, 25, 59-72.e8	23.4	56
23	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. *Journal of Infectious Diseases*, **2018**, 218, 633-644	7	23
22	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. *Journal of Virology*, **2018**, 92,	6.6	8
21	Therapeutic vaccination for HIV: hopes and challenges. *Current Opinion in HIV and AIDS*, **2018**, 13, 408-415	4.2	19
20	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). *Lancet, The*, **2018**, 392, 232-243	40	170
19	Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. *Journal of Virology*, **2018**, 92,	6.6	6
18	Zika virus vaccines. *Nature Reviews Microbiology*, **2018**, 16, 594-600	22.2	67
17	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. *Lancet, The*, **2018**, 391, 563-571	40	126
16	First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. *PLoS ONE*, **2018**, 13, e0205139	3.7	20
15	Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate. *Blood Advances*, **2018**, 2, 2917-2921	7.8	6
14	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. *Nature*, **2016**, 540, 284-287	50.4	183
13	Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4 T cell responses that impair CD8 T cell function. *Science Immunology*, **2016**, 1,	28	12
12	New concepts in HIV-1 vaccine development. *Current Opinion in Immunology*, **2016**, 41, 39-46	7.8	58
11	Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. *Open Forum Infectious Diseases*, **2016**, 3, ofw100	1	12
10	Broadly Neutralizing Antibodies for HIV Eradication. *Current HIV/AIDS Reports*, **2016**, 13, 31-7	5.9	62
9	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. *Science*, **2016**, 353, 1129-32	33.3	386
8	Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization. *Vaccine Journal*, **2015**, 22, 1166-75		8
7	Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. *Journal of Immunological Methods*, **2015**, 416, 105-23	2.5	31

6	Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys. *Journal of Virology*, **2014**, 88, 13510-5	6.6	5
5	A global approach to HIV-1 vaccine development. *Immunological Reviews*, **2013**, 254, 295-304	11.3	50
4	Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. *Journal of Virology*, **2012**, 86, 9583-9	6.6	35
3	Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. *Journal of Virology*, **2012**, 86, 11434-40	6.6	40
2	Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. *Journal of Infectious Diseases*, **2012**, 205, 1806-10	7	15
1	Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant		5